Patents by Inventor Mihriban Tuna
Mihriban Tuna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132599Abstract: The present invention provides multispecific antibodies comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V?1) chain of a ?? T cell receptor (TCR); and the Fe region comprises an EGFR binding site. The present invention also provides compositions and pharmaceutical compositions comprising such multispecific antibodies, and method of making such multispecific antibodies. The present invention also provides methods of treatment and medical uses involving the multispecific antibodies.Type: ApplicationFiled: August 16, 2023Publication date: April 25, 2024Inventors: Mihriban Tuna, Mark Uden, Joshua Freedman, Natalie Mount
-
Publication number: 20230406935Abstract: The application relates to specific binding members which bind to programmed death-ligand 1 (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.Type: ApplicationFiled: December 8, 2022Publication date: December 21, 2023Applicant: F-star Therapeutics LimitedInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
-
Publication number: 20230357413Abstract: The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.Type: ApplicationFiled: February 8, 2023Publication date: November 9, 2023Applicant: F-STAR THERAPEUTICS LIMITEDInventors: Mihriban Tuna, Kin-Mei Leung, Haijun Sun, Melanie Medcalf, Samine Isaac
-
Publication number: 20230348601Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.Type: ApplicationFiled: February 27, 2023Publication date: November 2, 2023Inventors: Matthew John MCCOURT, Richard Charles Alfred SAINSON, Jamie Iain CAMPBELL, Stephen John ARKINSTALL, Mihriban TUNA, Ryan FIEHLER, Mustapha FAROUDI, Fadi BADR, Francisca WOLLERTON VAN HORCK, Frederick AKELE
-
Patent number: 11629189Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.Type: GrantFiled: December 19, 2018Date of Patent: April 18, 2023Assignee: KYMAB LIMITEDInventors: Matthew John McCourt, Richard Charles Alfred Sainson, Jamie Iain Campbell, Stephen John Arkinstall, Mihriban Tuna, Ryan Fiehler, Mustapha Faroudi, Fadi Badr, Francisca Wollerton Van Horck, Frederick Akele
-
Patent number: 11629193Abstract: The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.Type: GrantFiled: July 19, 2017Date of Patent: April 18, 2023Assignee: F-star Therapeutics LimitedInventors: Mihriban Tuna, Kin-Mei Leung, Haijun Sun, Melanie Medcalf, Samine Isaac
-
Publication number: 20230028110Abstract: The present invention provides high-affinity anti-TCR delta variable 1 (anti-V?1) antibodies and antibody fragments thereof. The present invention also provides compositions and pharmaceutical compositions comprising such antibodies, and method of making such antibodies. The present invention also provides methods of treatment and medical uses involving the antibodies.Type: ApplicationFiled: February 17, 2022Publication date: January 26, 2023Applicant: Adaptate Biotherapeutics Ltd.Inventors: Mihriban TUNA, Oxana POLYAKOVA, Mark UDEN, Robert GOOD, Joshua FREEDMAN, Shefali BHUMBRA, Natalie MOUNT, Aoife MCGINLEY, Dan FOXLER
-
Patent number: 11548948Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.Type: GrantFiled: December 19, 2018Date of Patent: January 10, 2023Assignee: F-star Therapeutics LimitedInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
-
Publication number: 20220267421Abstract: The present application relates to antibody molecules that bind mesothelin (MSLN). The antibody molecules find application in the treatment and diagnosis of diseases and disorders, such as cancer.Type: ApplicationFiled: July 12, 2019Publication date: August 25, 2022Applicant: F-star Beta LimitedInventors: Jose Munoz-Olaya, Remi Fertin, Francisca Wollerton, Mihriban Tuna, Neil Brewis
-
Publication number: 20220185890Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.Type: ApplicationFiled: November 23, 2021Publication date: June 16, 2022Applicant: F-star Therapeutics LimitedInventors: Mihriban Tuna, Francisca Wollerton, Katy Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
-
Publication number: 20220185894Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.Type: ApplicationFiled: November 23, 2021Publication date: June 16, 2022Applicant: F-star Therapeutics LimitedInventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
-
Publication number: 20220119539Abstract: The invention relates to specific binding members that bind CD137. The specific binding members comprise a CD137 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.Type: ApplicationFiled: July 12, 2019Publication date: April 21, 2022Applicant: F-star Beta LimitedInventors: Matthew Lakins, Jose Munoz-Olaya, Sarka Pechouckova, Mihriban Tuna
-
Publication number: 20220048996Abstract: The present application relates to antibody molecules that bind and are able to agonise both CD137 and OX40. The antibody molecules comprise a CDR-based binding site for CD137, and an OX40 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer and infectious diseases.Type: ApplicationFiled: July 12, 2019Publication date: February 17, 2022Applicant: F-star Beta LimitedInventors: Mihriban Tuna, Miguel Gaspar, Michelle Morrow, Edmund Poon
-
Publication number: 20220049007Abstract: The present application relates to antibody molecules that bind both PD-L1 and CD 137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.Type: ApplicationFiled: July 12, 2019Publication date: February 17, 2022Applicant: F-star Beta LimitedInventors: Matthew Lakins, Jose Munoz-Olaya, Francisca Wollerton, Sarah Batey, Mihriban Tuna, Alexander Koers
-
Patent number: 11214618Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.Type: GrantFiled: June 20, 2017Date of Patent: January 4, 2022Assignee: F-star Therapeutics LimitedInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
-
Patent number: 11214620Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.Type: GrantFiled: June 20, 2017Date of Patent: January 4, 2022Assignee: F-star Therapeutics LimitedInventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
-
Publication number: 20210355228Abstract: The application relates to specific binding members that bind OX40. The specific binding members comprise an OX40 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.Type: ApplicationFiled: July 12, 2019Publication date: November 18, 2021Applicant: F-star Beta LimitedInventors: Mihriban Tuna, Miguel Gaspar, Sandra Uhlenbroich, Katy Everett, Delphine Buffet
-
Publication number: 20210309753Abstract: The present invention relates to antibody molecules that bind both mesothelin (MSLN) and CD137. The antibody molecules comprise a CDR-based binding site for MSLN, and a CD137 antigen-binding site located in a constant domain of the antibody molecule. The antibody molecules find application in the treatment of cancer, for example.Type: ApplicationFiled: July 12, 2019Publication date: October 7, 2021Applicant: F-star Delta LimitedInventors: Jose Munoz-Olaya, Mihriban Tuna, Remi Fertin, Claire Reader, Francisca Wollerton, Neil Brewis
-
Publication number: 20210277134Abstract: The invention relates to specific binding members that bind CD137. The specific binding members comprise a CD137 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.Type: ApplicationFiled: July 12, 2019Publication date: September 9, 2021Applicant: F-star Beta LimitedInventors: Matthew Lakins, Jose Munoz-Olaya, Sarka Pechouckova, Mihriban Tuna
-
Publication number: 20210139590Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.Type: ApplicationFiled: December 19, 2018Publication date: May 13, 2021Applicant: F-STAR BETA LIMITEDInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev